BetaClick for Previous Website
banner

Innovations in Cancer Research: Translating “OMICS” to Therapeutics

The Directorate of Research and Innovation, Nirma University organised a two-dayNational Symposium on, “Innovations in Cancer Research Targeting ‘OMICS’ to Therapeutics”,during September 14-15, 2018. The symposium was sponsored by the Science Engineering Research Board (SERB), Department of Science and Technology, Government of India and the Gujarat Council of Science & Technology (GUJCOST), Government of Gujarat. Approximately 130 participants including 35 faculty members /young researchers and 95 post-graduate /doctoral students attended the symposium. The participants were from The Gujarat Cancer & Research Institute, also from Indian Institute of technology, Gandhinagar, Gujarat University, Ahmedabad University, PERD Center, M.S. University, Supratech research laboratories and the several organizations within Gujarat and from our Institute of Science and Institute of Pharmacy, etc. During the symposium, nine nationally eminent and internationality recognized scientists delivered their talks and have also shared their valuable experiences and knowledge.   The areas like, Cancer Genomics, Cancer Proteomics, Cancer Transcriptomics, and Cancer stem cell, Cancer Immunology and Immunotherapy, Molecular Oncology, etc. are covered during the deliberations. In addition, there was a Panel Discussion Session on, “TARGETED THERAPIES IN CANCER” in which the current status of the targeted therapies and its implementation and future were discussed. There was a Poster Competition, in which fifty two posters were presented by the young researchers, doctoral students and the post-graduate students. During these two days, the participants got familiarized with the current concepts, technologies and clinical applicability of the knowledge in the area of oncology. In this symposium, the need of translational cancer research, identification of newer cancer therapeutics and implementation of personalized medicine were discussed at length.

Get our Newsletter